Tag: GlobeNewswire

GEORGE TOWN, Cayman Islands, Oct. 06, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for September 2026 on Tuesday, October 6, 2026.

These metrics include trading volume, average trading spread, and measures of volatility for Bitcoin and Ethereum. For definitions and additional information regarding these metrics, please refer to the monthly metrics packages available on investors.bullish.com.

About Bullish

Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange – an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data – a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights – a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Contacts

Media: media@bullish.com

Investor Relations: investors@bullish.com

Source: Bullish

Additional Information & Disclosures

This monthly metrics package provides certain limited purpose monthly performance results of Bullish. This information is presented without commentary and should be read together with our most recent quarterly and annual results and our filings with the U.S. Securities and Exchange Commission (SEC), which are available on our Investor Relations website at investors.bullish.com.

The information provided is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on our estimates and subject to completion of our financial closing procedures. Final results for the quarter, as reported in our SEC filings, might vary from the information provided in this monthly metrics package.

Bullish expects to release monthly metrics packages for the prior month’s performance after the end of each month.

We use our Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the SEC and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Definitions

Trading Volume represents the notional value of trades, i.e. the product of the quantity of assets transacted and the trade price at the time the transaction was executed. The quantity represents the total U.S. dollar equivalent value of matched trades transacted between a buyer and seller through our platform during the period of measurement.

Average Trading Spread represents total commissions earned from transactions on the Bullish Exchange for the period, expressed as a percentage of the trading volume for the period. Management reviews this metric, which reflects the cost of trading on the Bullish Exchange, changes in fair value of perpetual futures, and rebates, for insight into the average revenue generated per unit of trading volume on our platform.

Volatility is calculated using 1-minute price intervals from Coindesk Data’s Adaptive Diversified Liquidity Index for BTC and ETH. We determine the daily volatility by measuring the standard deviation of these minute-by-minute price changes, which provides a more granular view of price fluctuations. This daily figure is then converted to an annualized volatility by multiplying it by the square root of 365, a standard practice for making risk metrics comparable over a one-year period.

Monthly Metrics Report for September 2026
(Unaudited)
	2025													2026
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep
(B – in billions)
Trading Volume ($B)
Spot – BTC	34.6	30.9	43.2	39.2	32.8	19.9	20.8	18.2	16.4	38.2	38.4	25.9		22.5	41.8	29.1	20.9	16.8	26.9	16.7	17.6	19.9
Spot – ETH	18.3	19.2	14.9	10.9	12.0	9.5	11.1	12.8	8.8	15.1	14.1	9.6		8.4	12.9	8.0	5.4	3.4	4.9	3.0	3.7	4.5
Spot – Stablecoin	19.4	20.9	17.0	13.3	10.3	8.1	12.9	8.6	8.1	19.6	18.4	13.8		11.2	19.0	13.2	9.6	7.4	10.8	7.3	7.9	9.5
Spot – Other	4.8	3.8	2.7	2.2	2.6	2.4	4.0	4.6	4.1	4.6	4.4	2.9		3.4	3.7	2.7	2.1	2.5	2.9	2.2	6.6	8.4
Total Spot	77.1	74.8	77.7	65.5	57.6	39.9	48.8	44.3	37.3	77.5	75.3	52.2		45.4	77.4	52.9	38.0	30.0	45.5	29.1	35.8	42.2
Options								0.0	0.0	0.0	2.8	6.2		4.8	3.6	3.2	5.6	0.9	2.3	0.2	4.7	4.1
Perpetual	6.6	7.8	8.0	6.8	5.8	4.1	5.0	4.6	2.2	3.0	2.7	2.6		2.0	3.1	4.4	3.4	2.0	3.1	1.5	2.0	2.3
Total Trading Volume	83.7	82.5	85.7	72.3	63.4	44.0	53.8	48.8	39.6	80.5	80.8	61.1		52.2	84.1	60.4	46.9	32.9	50.9	30.7	42.5	48.6
Average Trading Spread (bps)
Spot	2.14	1.97	1.87	1.65	1.55	1.58	1.76	2.55	1.96	1.75	1.94	1.82		1.74	2.22	2.01	2.05	2.40	2.84	2.71	2.53	2.41
Options								1.00	0.93	1.29	1.34	1.66		1.95	2.42	1.86	2.50	1.65	0.59	1.09	0.14	0.40
Perpetual	(1.06)	(1.41)	(2.38)	(1.47)	(0.86)	(1.22)	(0.80)	(0.65)	0.21	(2.67)	(0.13)	(0.30)		(0.61)	0.37	0.09	(0.08)	(0.12)	(0.14)	1.21	(0.32)	0.38
Average Trading Spread	1.90	1.65	1.47	1.36	1.32	1.32	1.52	2.25	1.86	1.59	1.85	1.71		1.67	2.16	1.86	1.95	2.23	2.56	2.62	2.13	2.14
Monthly Average Volatility
BTC	48%	44%	50%	44%	33%	28%	27%	28%	23%	38%	45%	39%		33%	61%	48%	35%	28%	47%	32%	30%	32%
ETH	60%	78%	69%	70%	67%	54%	54%	60%	42%	58%	68%	53%		46%	82%	60%	44%	36%	67%	44%	39%	42%
* Figures presented may not sum precisely due to rounding

GEORGE TOWN, Cayman Islands, Oct. 06, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for September 2026 on Tuesday, October 6, 2026.

These metrics include trading volume, average trading spread, and measures of volatility for Bitcoin and Ethereum. For definitions and additional information regarding these metrics, please refer to the monthly metrics packages available on investors.bullish.com.

About Bullish

Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange – an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data – a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights – a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Contacts

Media: media@bullish.com

Investor Relations: investors@bullish.com

Source: Bullish

Additional Information & Disclosures

This monthly metrics package provides certain limited purpose monthly performance results of Bullish. This information is presented without commentary and should be read together with our most recent quarterly and annual results and our filings with the U.S. Securities and Exchange Commission (SEC), which are available on our Investor Relations website at investors.bullish.com.

The information provided is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on our estimates and subject to completion of our financial closing procedures. Final results for the quarter, as reported in our SEC filings, might vary from the information provided in this monthly metrics package.

Bullish expects to release monthly metrics packages for the prior month’s performance after the end of each month.

We use our Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the SEC and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Definitions

Trading Volume represents the notional value of trades, i.e. the product of the quantity of assets transacted and the trade price at the time the transaction was executed. The quantity represents the total U.S. dollar equivalent value of matched trades transacted between a buyer and seller through our platform during the period of measurement.

Average Trading Spread represents total commissions earned from transactions on the Bullish Exchange for the period, expressed as a percentage of the trading volume for the period. Management reviews this metric, which reflects the cost of trading on the Bullish Exchange, changes in fair value of perpetual futures, and rebates, for insight into the average revenue generated per unit of trading volume on our platform.

Volatility is calculated using 1-minute price intervals from Coindesk Data’s Adaptive Diversified Liquidity Index for BTC and ETH. We determine the daily volatility by measuring the standard deviation of these minute-by-minute price changes, which provides a more granular view of price fluctuations. This daily figure is then converted to an annualized volatility by multiplying it by the square root of 365, a standard practice for making risk metrics comparable over a one-year period.

Monthly Metrics Report for September 2026
(Unaudited)
	2025													2026
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep
(B – in billions)
Trading Volume ($B)
Spot – BTC	34.6	30.9	43.2	39.2	32.8	19.9	20.8	18.2	16.4	38.2	38.4	25.9		22.5	41.8	29.1	20.9	16.8	26.9	16.7	17.6	19.9
Spot – ETH	18.3	19.2	14.9	10.9	12.0	9.5	11.1	12.8	8.8	15.1	14.1	9.6		8.4	12.9	8.0	5.4	3.4	4.9	3.0	3.7	4.5
Spot – Stablecoin	19.4	20.9	17.0	13.3	10.3	8.1	12.9	8.6	8.1	19.6	18.4	13.8		11.2	19.0	13.2	9.6	7.4	10.8	7.3	7.9	9.5
Spot – Other	4.8	3.8	2.7	2.2	2.6	2.4	4.0	4.6	4.1	4.6	4.4	2.9		3.4	3.7	2.7	2.1	2.5	2.9	2.2	6.6	8.4
Total Spot	77.1	74.8	77.7	65.5	57.6	39.9	48.8	44.3	37.3	77.5	75.3	52.2		45.4	77.4	52.9	38.0	30.0	45.5	29.1	35.8	42.2
Options								0.0	0.0	0.0	2.8	6.2		4.8	3.6	3.2	5.6	0.9	2.3	0.2	4.7	4.1
Perpetual	6.6	7.8	8.0	6.8	5.8	4.1	5.0	4.6	2.2	3.0	2.7	2.6		2.0	3.1	4.4	3.4	2.0	3.1	1.5	2.0	2.3
Total Trading Volume	83.7	82.5	85.7	72.3	63.4	44.0	53.8	48.8	39.6	80.5	80.8	61.1		52.2	84.1	60.4	46.9	32.9	50.9	30.7	42.5	48.6
Average Trading Spread (bps)
Spot	2.14	1.97	1.87	1.65	1.55	1.58	1.76	2.55	1.96	1.75	1.94	1.82		1.74	2.22	2.01	2.05	2.40	2.84	2.71	2.53	2.41
Options								1.00	0.93	1.29	1.34	1.66		1.95	2.42	1.86	2.50	1.65	0.59	1.09	0.14	0.40
Perpetual	(1.06)	(1.41)	(2.38)	(1.47)	(0.86)	(1.22)	(0.80)	(0.65)	0.21	(2.67)	(0.13)	(0.30)		(0.61)	0.37	0.09	(0.08)	(0.12)	(0.14)	1.21	(0.32)	0.38
Average Trading Spread	1.90	1.65	1.47	1.36	1.32	1.32	1.52	2.25	1.86	1.59	1.85	1.71		1.67	2.16	1.86	1.95	2.23	2.56	2.62	2.13	2.14
Monthly Average Volatility
BTC	48%	44%	50%	44%	33%	28%	27%	28%	23%	38%	45%	39%		33%	61%	48%	35%	28%	47%	32%	30%	32%
ETH	60%	78%	69%	70%	67%	54%	54%	60%	42%	58%	68%	53%		46%	82%	60%	44%	36%	67%	44%	39%	42%
* Figures presented may not sum precisely due to rounding

Stockholm, 6 October 2026 – Virtune, a Swedish regulated digital asset manager, is announcing the launch of the Virtune Zcash ETP on Nasdaq Stockholm, the largest stock exchange in the Nordics.

Virtune is a Swedish asset manager and issuer of physically backed crypto exchange-traded products (ETPs). Since its launch in 2023, Virtune has gained the trust of more than 160,000 investors and today manages approximately USD 380 million in assets under management (AUM), strengthening the company’s position as one of Europe’s leading issuers of regulated crypto ETPs. The company holds more than 90% market share for crypto ETNs on Nasdaq Nordics.

About Virtune Zcash ETP

Virtune Zcash ETP is a physically backed exchange-traded product (ETP) designed to offer investors a secure and cost-effective way to gain exposure to Zcash (ZEC). This is made possible through a transparent and physically backed structure with institutional-level security.

Key information about Virtune Zcash ETP

• 1:1 exposure to ZEC
• 100% physically backed by ZEC
• 1.49% annual management fee

Virtune Zcash ETP

• Full name: Virtune Zcash ETP
• Short name: Virtune Zcash
• Ticker: VIRZEC
• Trading currency: SEK
• First day of trading: Tuesday, 6 October 2026
• ISIN: SE0030587929

About Zcash

Zcash is a payment blockchain with the option to protect payment details. Its crypto asset, ZEC, is used for payments. Launched in 2016 and built from Bitcoin’s original code, the network focuses on payment privacy. Users can choose between transparent and shielded addresses. Shielded payments use zero-knowledge proofs, a technology that lets the network verify a payment without publishing its underlying information. ZEC has a maximum supply of 21 million units.

Christopher Kock, CEO of Virtune:

“In May 2023, we launched our first product on Nasdaq Stockholm. Since then, we have worked tirelessly to expand our product offering and help Nordic investors better understand crypto assets. Today, we are pleased to introduce Virtune Zcash ETP, providing a straightforward way to gain exposure to Zcash through online brokers such as Avanza and Nordnet. The product is 100% physically backed by Zcash, held in cold storage with Coinbase.”

If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, covering updates on upcoming ETP launches and other news related to digital assets.

Press contact

Christopher Kock, CEO Virtune AB (Publ)
christopher@virtune.com
+46 70 073 45 64

Virtune, headquartered in Stockholm, is a Swedish regulated asset manager and issuer of crypto ETPs listed on regulated European exchanges. Through regulatory compliance, strategic partnerships and an experienced team, Virtune provides access to innovative and sophisticated investment products tailored to the rapidly evolving global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

Stockholm, 6 October 2026 – Virtune, a Swedish regulated digital asset manager, is announcing the launch of the Virtune Zcash ETP on Nasdaq Stockholm, the largest stock exchange in the Nordics.

Virtune is a Swedish asset manager and issuer of physically backed crypto exchange-traded products (ETPs). Since its launch in 2023, Virtune has gained the trust of more than 160,000 investors and today manages approximately USD 380 million in assets under management (AUM), strengthening the company’s position as one of Europe’s leading issuers of regulated crypto ETPs. The company holds more than 90% market share for crypto ETNs on Nasdaq Nordics.

About Virtune Zcash ETP

Virtune Zcash ETP is a physically backed exchange-traded product (ETP) designed to offer investors a secure and cost-effective way to gain exposure to Zcash (ZEC). This is made possible through a transparent and physically backed structure with institutional-level security.

Key information about Virtune Zcash ETP

• 1:1 exposure to ZEC
• 100% physically backed by ZEC
• 1.49% annual management fee

Virtune Zcash ETP

• Full name: Virtune Zcash ETP
• Short name: Virtune Zcash
• Ticker: VIRZEC
• Trading currency: SEK
• First day of trading: Tuesday, 6 October 2026
• ISIN: SE0030587929

About Zcash

Zcash is a payment blockchain with the option to protect payment details. Its crypto asset, ZEC, is used for payments. Launched in 2016 and built from Bitcoin’s original code, the network focuses on payment privacy. Users can choose between transparent and shielded addresses. Shielded payments use zero-knowledge proofs, a technology that lets the network verify a payment without publishing its underlying information. ZEC has a maximum supply of 21 million units.

Christopher Kock, CEO of Virtune:

“In May 2023, we launched our first product on Nasdaq Stockholm. Since then, we have worked tirelessly to expand our product offering and help Nordic investors better understand crypto assets. Today, we are pleased to introduce Virtune Zcash ETP, providing a straightforward way to gain exposure to Zcash through online brokers such as Avanza and Nordnet. The product is 100% physically backed by Zcash, held in cold storage with Coinbase.”

If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, covering updates on upcoming ETP launches and other news related to digital assets.

Press contact

Christopher Kock, CEO Virtune AB (Publ)
christopher@virtune.com
+46 70 073 45 64

Virtune, headquartered in Stockholm, is a Swedish regulated asset manager and issuer of crypto ETPs listed on regulated European exchanges. Through regulatory compliance, strategic partnerships and an experienced team, Virtune provides access to innovative and sophisticated investment products tailored to the rapidly evolving global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

FORT WORTH, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — RANGE RESOURCES CORPORATION (NYSE: RRC) announced today that its third quarter 2026 financial results news release will be issued Tuesday, October 27 after the close of trading on the New York Stock Exchange.

A conference call to review the financial results is scheduled on Wednesday, October 28 at 9:00 a.m. ET (8:00 a.m. CT). A webcast of the call may be accessed at www.rangeresources.com. The webcast will be archived for replay on the Company’s website until November 27, 2026.

RANGE RESOURCES CORPORATION (NYSE: RRC) is a leading U.S. independent natural gas and NGL producer with operations focused in the Appalachian Basin. The Company is headquartered in Fort Worth, Texas. More information about Range can be found at www.rangeresources.com.

SOURCE: Range Resources Corporation

Range Investor Contacts:

Laith Sando, SVP – Corporate Strategy & Investor Relations
817-869-4267
lsando@rangeresources.com

FORT WORTH, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — RANGE RESOURCES CORPORATION (NYSE: RRC) announced today that its third quarter 2026 financial results news release will be issued Tuesday, October 27 after the close of trading on the New York Stock Exchange.

A conference call to review the financial results is scheduled on Wednesday, October 28 at 9:00 a.m. ET (8:00 a.m. CT). A webcast of the call may be accessed at www.rangeresources.com. The webcast will be archived for replay on the Company’s website until November 27, 2026.

RANGE RESOURCES CORPORATION (NYSE: RRC) is a leading U.S. independent natural gas and NGL producer with operations focused in the Appalachian Basin. The Company is headquartered in Fort Worth, Texas. More information about Range can be found at www.rangeresources.com.

SOURCE: Range Resources Corporation

Range Investor Contacts:

Laith Sando, SVP – Corporate Strategy & Investor Relations
817-869-4267
lsando@rangeresources.com

CHANTILLY, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) will release third-quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The company will host a conference call at 8:00 a.m. Eastern Time that day to discuss its earnings results and guidance, followed by a question-and-answer session.

Access to a webcast of the live conference call can be obtained through the Investor Relations section of the company’s website (https://investors.parsons.com). Those parties interested in participating via telephone may register on the Investor Relations website or by clicking here.

A replay will be available on the company’s website approximately two hours after the conference call and continuing for one year.

About Parsons Corporation

Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Contacts:

Media
Bernadette Miller
Parsons Corporation
+1 980.253.9781
Bernadette.Miller@parsons.com

Investor Relations
Dave Spille
Parsons Corporation
+1 571.775.0408
Dave.Spille@Parsons.us

CHANTILLY, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) will release third-quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The company will host a conference call at 8:00 a.m. Eastern Time that day to discuss its earnings results and guidance, followed by a question-and-answer session.

Access to a webcast of the live conference call can be obtained through the Investor Relations section of the company’s website (https://investors.parsons.com). Those parties interested in participating via telephone may register on the Investor Relations website or by clicking here.

A replay will be available on the company’s website approximately two hours after the conference call and continuing for one year.

About Parsons Corporation

Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Contacts:

Media
Bernadette Miller
Parsons Corporation
+1 980.253.9781
Bernadette.Miller@parsons.com

Investor Relations
Dave Spille
Parsons Corporation
+1 571.775.0408
Dave.Spille@Parsons.us

• Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome
• Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program

ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” has been accepted for publication in a forthcoming issue of Dermatology and Therapy.

The peer-reviewed paper introduces QRX003, the Company’s investigational topical serine protease inhibitor lotion, and describes its mechanism of action in Netherton Syndrome. It also presents a case report from Professor Alan Irvine, consultant dermatologist at Children’s Health Ireland and professor of dermatology at Trinity College Dublin, describing his positive clinical experience treating a pediatric patient with QRX003 under Quoin’s Pediatric Compassionate Use Program. The paper describes the impact that QRX003 has had on the patient leading to fully healed skin, complete elimination of pruritus (itch) which has led to zero nightly sleep disturbances as a result and significant reduction in need for all previously required medications.

In June, Quoin reported that four of the six pediatric patients then enrolled in the Compassionate Use Program were classified as ‘Improved’ or ‘Significantly Improved’ from baseline across key clinical endpoints, with no treatment-related adverse events reported.

Separately, in August Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in Netherton Syndrome. In the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215).

“Acceptance of this paper by a peer-reviewed dermatology journal is important recognition of the scientific rationale behind QRX003 and its potential in Netherton Syndrome. We are grateful to Professor Irvine for documenting his clinical experience treating a pediatric patient with QRX003,” said Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals. “Because Netherton Syndrome is a genetic disease, the experience of pediatric patients is especially important as we advance QRX003. This case report adds to the growing body of clinical evidence supporting the program, including the positive interim results from our ongoing Phase 2/3 study.”

About Netherton Syndrome

Netherton Syndrome is a rare, serious genetic skin disease caused by mutations in the SPINK5 gene. The condition is characterized by impaired skin barrier function, persistent inflammation, and increased serine protease activity in the skin. There are currently no approved therapies in the United States indicated specifically for Netherton Syndrome.

About QRX003

QRX003 is an investigational topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome and other orphan skin diseases. QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the U.S. Food and Drug Administration, and Orphan Drug Designation in the European Union and Japan. QRX003 lotion (4%) is currently being evaluated in whole-body clinical trials in patients with Netherton Syndrome, including the Phase 2/3 study CL-QRX003-004.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Cautionary Note Regarding Forward Looking Statements

The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: QRX003 potentially becoming the first approved treatment for Netherton Syndrome; QRX003 having the potential to change the course of Netherton Syndrome in patients treated with this product; and Quoin’s belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, microcystic lymphatic malformations, venous malformations, angiofibromas and others.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

For further information, contact:

Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com

Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341

• Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome
• Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use Program

ASHBURN, Va., Oct. 06, 2026 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that a manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” has been accepted for publication in a forthcoming issue of Dermatology and Therapy.

The peer-reviewed paper introduces QRX003, the Company’s investigational topical serine protease inhibitor lotion, and describes its mechanism of action in Netherton Syndrome. It also presents a case report from Professor Alan Irvine, consultant dermatologist at Children’s Health Ireland and professor of dermatology at Trinity College Dublin, describing his positive clinical experience treating a pediatric patient with QRX003 under Quoin’s Pediatric Compassionate Use Program. The paper describes the impact that QRX003 has had on the patient leading to fully healed skin, complete elimination of pruritus (itch) which has led to zero nightly sleep disturbances as a result and significant reduction in need for all previously required medications.

In June, Quoin reported that four of the six pediatric patients then enrolled in the Compassionate Use Program were classified as ‘Improved’ or ‘Significantly Improved’ from baseline across key clinical endpoints, with no treatment-related adverse events reported.

Separately, in August Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in Netherton Syndrome. In the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215).

“Acceptance of this paper by a peer-reviewed dermatology journal is important recognition of the scientific rationale behind QRX003 and its potential in Netherton Syndrome. We are grateful to Professor Irvine for documenting his clinical experience treating a pediatric patient with QRX003,” said Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals. “Because Netherton Syndrome is a genetic disease, the experience of pediatric patients is especially important as we advance QRX003. This case report adds to the growing body of clinical evidence supporting the program, including the positive interim results from our ongoing Phase 2/3 study.”

About Netherton Syndrome

Netherton Syndrome is a rare, serious genetic skin disease caused by mutations in the SPINK5 gene. The condition is characterized by impaired skin barrier function, persistent inflammation, and increased serine protease activity in the skin. There are currently no approved therapies in the United States indicated specifically for Netherton Syndrome.

About QRX003

QRX003 is an investigational topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome and other orphan skin diseases. QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the U.S. Food and Drug Administration, and Orphan Drug Designation in the European Union and Japan. QRX003 lotion (4%) is currently being evaluated in whole-body clinical trials in patients with Netherton Syndrome, including the Phase 2/3 study CL-QRX003-004.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Cautionary Note Regarding Forward Looking Statements

The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: QRX003 potentially becoming the first approved treatment for Netherton Syndrome; QRX003 having the potential to change the course of Netherton Syndrome in patients treated with this product; and Quoin’s belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, microcystic lymphatic malformations, venous malformations, angiofibromas and others.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

For further information, contact:

Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com

Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341